Read + Share
Amedeo Smart
Independent Medical Education
Tefferi A, Pardanani A, Gangat N. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. Haematologica 2023;108:2919-2932.PMID: 36861402
Email
LinkedIn
Facebook
Twitter
Privacy Policy